Sanofi (NASDAQ:SNY) Shares Purchased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD increased its holdings in Sanofi (NASDAQ:SNY - Free Report) by 88.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,843,682 shares of the company's stock after purchasing an additional 5,091,304 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.43% of Sanofi worth $522,991,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. State Street Corp lifted its position in shares of Sanofi by 0.5% during the 3rd quarter. State Street Corp now owns 56,734 shares of the company's stock valued at $3,270,000 after buying an additional 264 shares in the last quarter. Barclays PLC lifted its holdings in Sanofi by 107.5% during the third quarter. Barclays PLC now owns 639,772 shares of the company's stock valued at $36,869,000 after purchasing an additional 331,445 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Sanofi by 7.1% during the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company's stock valued at $14,681,000 after purchasing an additional 16,780 shares in the last quarter. World Investment Advisors LLC grew its position in shares of Sanofi by 1,020.5% in the third quarter. World Investment Advisors LLC now owns 48,430 shares of the company's stock valued at $2,791,000 after purchasing an additional 44,108 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of Sanofi during the third quarter worth about $219,000. Hedge funds and other institutional investors own 14.04% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on SNY shares. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. BNP Paribas began coverage on Sanofi in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Finally, The Goldman Sachs Group initiated coverage on shares of Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 target price on the stock. Three research analysts have rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $63.33.

Sanofi Price Performance

Shares of NASDAQ:SNY traded down $1.22 during midday trading on Friday, hitting $52.32. The company had a trading volume of 5,488,689 shares, compared to its average volume of 2,365,342. The business's 50-day simple moving average is $54.53 and its 200-day simple moving average is $52.05. The stock has a market cap of $132.17 billion, a price-to-earnings ratio of 21.01, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The business had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. On average, research analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be issued a dividend of $2.0369 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a dividend yield of 3.1%. This is an increase from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio (DPR) is currently 57.14%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.